cancer treatment

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

Novartis broke ground on a $46K sq. ft. radioligand therapy facility in Texas, the fifth RLT site supporting its $23B US manufacturing investment ending in 2028.

Novartis broke ground on a Texas radioligand therapy facility, the fifth in its US network, part of a $23 billion manufacturing investment expected operational by 2028.

Aktis Oncology presents miniprotein radioconjugate platform at BofA Securities conference, advancing AKY-1189 and AKY-2519 across solid tumor indications.

Iovance Biotherapeutics surged 34% in 2026 on strong melanoma drug sales, with analysts projecting 165% upside. Manufacturing challenges present significant execution risks.

EUDA's partner Shenzhen Inno Immune wins Chinese government R&D funding approval for TCR-T cell therapy development targeting solid tumors.

Global radiopharmaceuticals market projected to grow from $8.28B (2026) to $15.21B (2035) amid rising cancer and cardiovascular disease incidence.

ImmunityBio faces securities lawsuit after FDA warning over misleading Anktiva cancer claims. Stock drops 21%, erasing $2B market cap.

Eli Lilly stock fell 2.5% after announcing a $7 billion acquisition of Kelonia Therapeutics for CAR-T cancer therapy, despite positive analyst rating.

Bispecific antibody drug conjugates market projected at $2B+ by 2030, with first approval expected by 2028 amid 150+ global clinical trials.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.

Perspective Therapeutics reports 43% response rate for neuroendocrine tumor therapy with no serious safety issues, planning 2026 regulatory submissions.

Nanobiotix reports preclinical data showing nanoprimer technology improves DNA immunotherapy circulation while reducing hepatic toxicity in mouse models.

Biolojic Design presents preclinical data for BD200, a dual-target cancer drug showing superior efficacy against resistant tumors. Clinical trials expected in H2 2026.

Foghorn Therapeutics will present preclinical data on SMARCA2 and epigenetic degrader programs at AACR 2026, advancing pipeline with Eli Lilly partnership.

IN8bio issued 11,800 stock options to two new employees on April 1, 2026, as hiring incentives under Nasdaq listing regulations.

ImmunityBio faces securities lawsuit after FDA warns of misleading Anktiva efficacy claims. Stock plunges 21%, erasing $2B in market value.

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.